Core Viewpoint - Yuekang Pharmaceutical Group Co., Ltd. has submitted an application for H-share listing on the Hong Kong Stock Exchange, marking a significant step in its "A+H" dual-platform listing strategy, which aims to address its financial challenges and support R&D innovation [1][3]. Group 1: Company Overview - Yuekang Pharmaceutical, listed on the STAR Market, is transitioning to a dual listing in Hong Kong to create an international financing platform [1][3]. - The company has faced declining performance, with revenue dropping from 4.542 billion yuan in 2022 to 3.781 billion yuan in 2024, and net profit plummeting from 335 million yuan to 124 million yuan in the same period [6][7]. Group 2: Financial Challenges - The company's core product, Ginkgo Biloba Extract Injection, has seen a price reduction of approximately 53% due to regulatory scrutiny, leading to significant revenue loss and a quarterly loss of 86.01 million yuan in Q4 2024 [6][7]. - The reliance on a single product has weakened the company's risk resilience, exposing vulnerabilities in its product pipeline [7]. Group 3: Strategic Initiatives - The funds raised from the H-share listing are intended for R&D innovation and operational capital, which could alleviate financial pressures and revitalize stalled projects [10]. - The dual listing structure is expected to enhance liquidity and provide a valuation anchor based on the existing A-share market [10]. Group 4: Market Sentiment and Risks - Investors are cautious, weighing the potential for recovery against ongoing risks, including high sales costs and governance concerns stemming from the controlling shareholder's legal issues [9][11]. - The market perceives the recent price adjustments as a potential turning point, suggesting that the worst may be over, but uncertainties regarding profitability recovery remain [10][11]. Group 5: IPO Details - The IPO timeline is pending, with details such as the offering price and allocation mechanisms yet to be announced [13]. - The company plans to establish a green shoe mechanism to stabilize pricing, allowing underwriters to exercise an over-allotment option of up to 15% of the initial offering size [13].

Core Viewpoint - The Hong Kong stock market is set to welcome Yuyuan Pharmaceutical Group Co., Ltd. as it officially submitted its H-share listing application to the Hong Kong Stock Exchange, marking a significant step in its dual-platform listing strategy [1][3]. Group 1: Company Overview - Yuyuan Pharmaceutical, listed on the STAR Market, aims to establish an international financing platform through its H-share listing, which is crucial for its research and development innovation and operational funding [3]. - The company has faced significant challenges, including a decline in revenue and profitability, with revenue dropping from 4.542 billion yuan in 2022 to 3.781 billion yuan in 2024, and net profit plummeting from 335 million yuan to 124 million yuan in the same period [6]. Group 2: Financial Performance - The company recorded a net loss of 49.27 million yuan in the first quarter of 2025, indicating ongoing financial difficulties [6]. - The decline in performance is primarily attributed to the price reduction of its flagship product, Ginkgo Biloba Extract Injection, which saw a price drop of approximately 53% due to regulatory scrutiny, leading to a quarterly loss of 86.01 million yuan in Q4 2024 [6]. Group 3: Business Structure and Challenges - Yuyuan Pharmaceutical's heavy reliance on a single product has weakened its risk resilience, with the Ginkgo product historically contributing nearly 60% of its revenue [7]. - The transition from generic drugs to innovative drugs has been slow, with only one new drug launched and several research projects delayed [7]. - The company has incurred high sales expenses, totaling 7.37 billion yuan from 2021 to 2024, raising concerns about its sales model and compliance [7]. Group 4: Market Sentiment and Investment Considerations - Investors are weighing the potential for a turnaround against ongoing risks, with the company's future performance heavily dependent on its ability to stabilize and innovate [9][10]. - The H-share fundraising is intended for R&D and operational support, which could alleviate financial pressures and revitalize stalled projects [10]. - The dual-listing structure may provide a valuation anchor and enhance liquidity, although the H-share price is expected to be at a discount to the A-share price [10]. Group 5: Upcoming IPO Details - The IPO timeline is yet to be announced, with the application currently under review [13]. - The total amount to be raised and the share price range are still pending, with the issuance expected to not exceed 15% of the total share capital post-issue [13]. - The presence of cornerstone investors will be a key indicator of market confidence in the company's recovery prospects [13].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's profit performance slightly exceeded expectations, with notable growth in the industrial and industrial microbiology segments [7] - In 2024, the company achieved total revenue of 41.906 billion yuan, representing a year-on-year growth of 3.16%, and a net profit attributable to shareholders of 3.512 billion yuan, up 23.72% year-on-year [7] - The industrial segment saw rapid growth, with core subsidiary China Medical East achieving sales revenue of 13.811 billion yuan, a 13.05% increase, and a net profit of 2.876 billion yuan, up 29.04% [7] - The industrial microbiology segment reported a significant revenue increase of 43.12%, with various sub-segments showing strong growth [7] - The aesthetic medicine segment experienced a decline in overseas revenue but maintained growth in domestic revenue, with total revenue of 2.326 billion yuan, down 4.94% year-on-year [7] - The company has a rich pipeline of products under development, focusing on oncology, endocrinology, and autoimmune diseases, with over 80 innovative drug candidates [7] - The profit forecast for 2025-2026 has been adjusted, with expected net profits of 4.014 billion yuan and 4.539 billion yuan, respectively, corresponding to a P/E ratio of 17 and 15 [7] Financial Summary - Total revenue for 2023 is projected at 40.624 billion yuan, with a year-on-year growth of 7.71% [1] - The net profit attributable to shareholders for 2023 is estimated at 2.839 billion yuan, reflecting a year-on-year increase of 13.59% [1] - The latest diluted EPS for 2023 is expected to be 1.62 yuan per share, with a P/E ratio of 24.30 [1] - The company’s total assets are projected to reach 37.879 billion yuan by 2024, with total liabilities of 14.315 billion yuan [8] - The cash flow from operating activities for 2024 is expected to be 3.749 billion yuan [8]